Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.

在38例风湿性关节炎患者的免疫抑制治疗和20例健康对照（HC）中评估了13价肺炎球菌多糖（PnPS）结合疫苗（PCV13）的免疫原性。在免疫后（T0），1（T1），6（T2），12（T3）个月之前测量所有PnPS和白喉毒素类似物缀合物蛋白的抗体。患者和HC对个体PnPS的反应相似。所有PnPS的平均抗体水平，但在T1时是T0的两倍，而T3持久性仅为8-7 / 13 PnPS。基线抗体水平与T1（T1 /T0≥2）至11/13 PnPS时的应答率成反比。在侵袭性肺炎球菌疾病的意大利患者中，很少有受试者针对一些经常分离出的血清型达到保护性IgG水平。抗体反应不受PS7F的一种治疗方法的影响，被肿瘤坏死因子-α抑制剂减少了。疫苗接种也增加了抗白喉IgG。尽管这项研究充分证实了免疫功能低下患者的PCV13免疫原性，但它也显示出一些局限性。